2seventy bio, Inc. (TSVT)
Largest Insider Buys in Sector
TSVT Stock Price History Chart
TSVT Stock Performance
About 2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Insider Activity of 2seventy bio, Inc.
Over the last 12 months, insiders at 2seventy bio, Inc. have bought $4.1M and sold $586,641 worth of 2seventy bio, Inc. stock.
On average, over the past 5 years, insiders at 2seventy bio, Inc. have bought $5.1M and sold $572,785 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Casdin Capital, LLC (director) — $12.31M.
The last purchase of 40,000 shares for transaction amount of $203,992 was made by Casdin Capital, LLC (director) on 2024‑03‑26.
List of Insider Buy and Sell Transactions, 2seventy bio, Inc.
| 2024-11-18 | Sale | director | 3,900 0.0076% | $3.38 | $13,182 | -8.88% | ||
| 2024-10-03 | Sale | Chief Financial Officer | 1,230 0.0023% | $4.65 | $5,718 | +1.16% | ||
| 2024-10-03 | Sale | See Remarks | 679 0.0013% | $4.65 | $3,157 | +1.16% | ||
| 2024-08-14 | Sale | See Remarks | 7,816 0.0156% | $4.32 | $33,760 | 0.00% | ||
| 2024-08-05 | Sale | Chief Financial Officer | 13 <0.0001% | $3.98 | $52 | +16.54% | ||
| 2024-07-02 | Sale | Chief Financial Officer | 12 <0.0001% | $4.02 | $48 | 0.00% | ||
| 2024-07-02 | Sale | See Remarks | 14 <0.0001% | $4.02 | $56 | 0.00% | ||
| 2024-06-03 | Sale | Chief Financial Officer | 1,167 0.0023% | $4.18 | $4,881 | +9.33% | ||
| 2024-06-03 | Sale | See Remarks | 649 0.0013% | $4.18 | $2,714 | +9.33% | ||
| 2024-05-03 | Sale | See Remarks | 15 <0.0001% | $4.91 | $74 | -4.21% | ||
| 2024-03-26 | director | 40,000 0.0812% | $5.10 | $203,992 | -7.46% | |||
| 2024-03-25 | director | 330,000 0.6747% | $5.07 | $1.67M | -6.33% | |||
| 2024-03-22 | director | 147,377 0.2903% | $5.12 | $754,069 | -10.43% | |||
| 2024-03-21 | director | 300,000 0.5822% | $4.90 | $1.47M | -8.18% | |||
| 2024-01-05 | Sale | President and CEO | 1,554 0.003% | $3.75 | $5,833 | +20.99% | ||
| 2024-01-05 | Sale | Chief Scientific Officer | 795 0.0015% | $3.75 | $2,984 | +20.99% | ||
| 2024-01-05 | Sale | Chief Operating Officer | 1,380 0.0027% | $3.75 | $5,180 | +20.99% | ||
| 2024-01-03 | Sale | President and CEO | 72,312 0.143% | $3.87 | $279,739 | +20.05% | ||
| 2024-01-03 | Sale | Chief Scientific Officer | 25,613 0.0506% | $3.87 | $99,084 | +20.05% | ||
| 2024-01-03 | Sale | Chief Operating Officer | 33,651 0.0665% | $3.87 | $130,179 | +20.05% |
Insider Historical Profitability
| Casdin Capital, LLC | director | 2000000 3.8837% | $3.65 | 4 | 0 | |
| Leschly Nick | President and CEO | 1085476 2.1078% | $3.65 | 1 | 10 | <0.0001% |
| Kynam Capital Management, LP | 10 percent owner | 5953825 11.5613% | $3.65 | 2 | 0 | |
| Kynam Global Healthcare Master Fund, LP | 10 percent owner | 5953825 11.5613% | $3.65 | 1 | 0 |
Institutional Investor Ownership
| Kynam Capital Management Lp | $31.85M | 11.58 | 5.95M | 0% | +$0 | 0.4 | |
| Morgan Stanley | $23.31M | 8.48 | 4.36M | -10.02% | -$2.6M | <0.01 | |
| Goldman Sachs | $22.59M | 8.21 | 4.22M | -6.37% | -$1.54M | <0.01 | |
| BlackRock | $20.89M | 7.6 | 3.91M | -0.16% | -$33,806.65 | <0.0001 | |
| The Vanguard Group | $19.96M | 7.26 | 3.73M | -6.38% | -$1.36M | <0.0001 |